The purpose of the study is to evaluate the appropriateness, adoption, feasibility, fidelity, and acceptability of implementation strategies and Cabotegravir (CAB) pre-exposure prophylaxis (PrEP). The study objectives are also to identify barriers and facilitators to implementation. The first of two participant types in the study are the Patient Study Participants (PSPs) will refer to individuals who are enrolled in the study and who will receive commercially available CAB PrEP via prescription from the PrEP provider. The second are Staff Study Participants (SSPs) who are site staff involved in the administrative and clinical aspects of offering and administering PrEP to PSPs at the clinical site.
1 Primary · 48 Secondary · Reporting Duration: Month 1, 4, 5, 12 and 13
250 Total Participants · 3 Treatment Groups
Primary Treatment: Enhanced Collaborative Implementation (ECI) · No Placebo Group · Phase 4
Age 18+ · Female Participants · 7 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: